Slide 1: Q2 2024 Financial Results
Q2 2024 Financial Results As of June 30, 2024 | Reported on August 8, 2024
Slide 2: Safe Harbor Statements
Safe Harbor Statements Certain statements contained in this presentation are "forward-looking statements” about future events and expectations. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our
Slide 3: © 2024 The Joint Corp. All Rights Reserved.
© 2024 The Joint Corp. All Rights Reserved. 3 3
Slide 4: Embracing Innovation
Embracing Innovation Initial Visit Enhanced Digital Clinic in-a-Box Bookings Intake Forms ©2024 The Joint Corp All Rights Reserved 4
Slide 5: Refranchising Vast Majority of Clinics
Refranchising Vast Majority of Clinics Completed initial transactions: • Sold into existing franchisees • Executing Letters of Intent Aggressively Marketing Clusters: • Engaged with Capstone Partners • Finalized Confidential Information Memo • Vetting potential franchisees Value maximization: • Gene
Slide 6: Building Brand Strategy
Building Brand Strategy Leveraging unique strengths to • Grow clinic profitability • Patient loyalty Executing new programs to • Support awareness campaigns • Amplify patient acquisition & retention • Engage lapsed patients • Increase referrals • Improve conversion & attrition Targeting huge opportu
Slide 7: Increasing Franchised Clinics
Increasing Franchised Clinics TOTAL CLINICS OPEN Q2 Q2 24 23 Franchised Company-owned and managed 960 Franchised 935 Clinics 9 23 838 135 131 Opened 126 Franchised 706 Clinics 1 4 96 Closed 579 Refranchised/ 513 64 (Acquired) 2 (3) 442 60 Clinics 399 370 48 800 829 47 Corporate 312 61 712 Clinics 0
Slide 8: Robust Development Pipeline
Robust Development Pipeline 7 158 1,270 Franchise licenses Clinics in active Gross cumulative franchise sold in Q2 2024 development 1 of June 30, 2024 licenses sold 1 of June 30, 2024 29% 59% 55% Franchise licenses sold Of clinics supported by Metropolitan statistical in Q2 2024 by 17 RDs as of June
Slide 9: Q2 2024 Financial Results as of June 30, 2024
Q2 2024 Financial Results as of June 30, 2024 $ in M 1 Q2 2024 Q2 2023 Differences Revenue $30.3 $29.3 $1.0 3% • Corporate clinics 17.7 17.8 (0.2) (1)% • Franchise fees and royalties 12.6 11.5 1.1 10% Cost of revenue 2.8 2.6 0.2 9% Sales and marketing 2 5.4 4.7 0.7 15% Depreciation and amortization
Slide 10: Strong Liquidity
Strong Liquidity $ in Ms 6/30/24 12/31/23 Unrestricted cash $17.5 $18.2 Restricted cash $1.2 $1.1 Available JP Morgan Chase LOC1 $20.0 $18.0 Cash flow for the six months end June 30, 2024: • $1.8M from operations • $224k from the net proceeds of the sales of clinics • $(2.0)M repayment of JPMorgan C
Slide 11: YTD 2024 Financial Results as of June 30, 2024
YTD 2024 Financial Results as of June 30, 2024 $ in M 1 6 mo.s 6/30/24 6 mo.s 6/30/23 Differences Revenue $60.0 $57.6 $2.4 4% • Corporate clinics 35.2 34.9 0.3 1% • Franchise fees and royalties 24.8 22.7 2.1 9% Cost of revenue 5.5 5.1 0.5 9% Sales and marketing 2 9.3 8.9 0.4 5% Depreciation and amor
Slide 12: Reiterating 2024 Guidance
Reiterating 2024 Guidance 2023 2024 Low 2024 High $ in M Actual Guidance Guidance System-wide sales 1 $488.0 $530 $545 System-wide comp sales for all clinics open 13 months or more 2 4% Mid-single digits New franchised clinic openings excluding the impact of refranchised clinics 104 60 75 1 System-w
Slide 13: Successful Annual Franchise Conference
Successful Annual Franchise Conference inspire influence imagine © 2024 The Joint Corp. All Rights Reserved. 13
Slide 14: Leading Chiropractic Care Franchise Concept
Leading Chiropractic Care Franchise Concept Large & Attractive Recurring Premier Category Growing Asset-light Revenue Nationwide Leader & Market Model Model Brand Creator $20.5B on 86% franchised 85% of 2023 41 state presence, 960 clinics at 6/30/24, chiropractic clinics and system-wide successful r
Slide 15: Chari Hawkins, Three-time Olympian Influencer
TITLE Chari Hawkins Three-time Olympian Influencer for The Joint IG Following: 959k © 2024 The Joint Corp. All Rights Reserved. 15
Slide 16: Performance Metrics and Non-GAAP Measures
Performance Metrics and Non-GAAP Measures This presentation of commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the inf
Slide 17: Q2 2024 Segment Results as of Jun. 30, 2024
Q2 2024 Segment Results as of Jun. 30, 2024 $ in 000s 2024 Q2 © 2024 © The 2024 Joint TheCorp. JointAll Corp. Rights All Reserved. Rights Reserved. 17
Slide 18: YTD 2024 Segment Results as of Jun. 30, 2024
YTD 2024 Segment Results as of Jun. 30, 2024 $ in 000s H1 2024 © 2024 © The 2024 Joint TheCorp. JointAll Corp. Rights All Reserved. Rights Reserved. 18
Slide 19: GAAP – Non-GAAP Reconciliation
GAAP – Non-GAAP Reconciliation $ in 000s Due to rounding, numbers may not add up precisely to the totals. © 2024 The Joint Corp. All Rights Reserved. 19
Slide 20: Contact: Peter D. Holt, Jake Singleton, Kirsten Chapman
Peter D. Holt, President & CEO peter.holt@thejoint.com peter.holt@thejoint.com The Joint Corp. | 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 | (480) 245-5960 https://www.facebook.com/thejointchiro https://www.facebook.com/thejointchiro @thejointchiro Jake Singleton, CFO https://twitter.c